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Abstract 
Multinodular and vacuolating neuronal tumour (MVNT) is a new pattern of neuronal tumour 
included in the recently revised WHO 2016 classification of tumours of the CNS. There are 
fifteen reports in the literature to date. They are typically associated with late onset epilepsy 
and a neoplastic versus malformative biology has been questioned. We present a series of 
ten cases and compare their pathological and genetic features to better characterised 
epilepsy associated malformations including focal cortical dysplasia type II (FCDII) and low-
grade epilepsy associated tumours (LEAT). Clinical and neuroradiology data were reviewed 
and a broad immunohistochemistry panel was applied to explore neuronal and glial 
differentiation, interneuronal populations, mTOR pathway activation and neurodegenerative 
changes. Next generation sequencing was performed for targeted multi-gene analysis to 
identify mutations common to epilepsy lesions including FCDII and LEAT. All of the surgical 
cases in this series presented with seizures, and were located in the temporal lobe. There 
was a lack of any progressive changes on serial pre-operative MRI and a mean age at 
surgery of 45 years. The vacuolated cells of the lesion expressed mature neuronal markers 
(neurofilament/SMI32, MAP2, synaptophysin). Prominent labelling of the lesional cells for 
developmentally regulated proteins (OTX1, TBR1, SOX2, MAP1b, CD34, GFAPδ) and 
oligodendroglial lineage markers (OLIG2, SMI94) was observed. No mutations were 
detected in the mTOR pathway genes, BRAF, FGFR1 or MYB. Clinical, pathological and 
genetic data could indicate that MVNT aligns more with a malformative lesion than a true 
neoplasm with origin from a progenitor neuro-glial cell type showing aberrant maturation. 
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Introduction 
Indolent cortical lesions provoking focal refractory epilepsy often bridge a gap between focal 
developmental anomalies and low grade tumours.  A long history of seizures and a lack of 
progressive neurology or MRI changes are characteristic of WHO grade I tumours, such as 
ganglioglioma and dysembryoplastic neuroepithelial tumours (DNT)(57).   However, many 
hamartomatous or developmental ‘overgrowth’  lesions, particularly the mTORopathies (13) 
or those associated with mutations in the PI3K–AKT signalling pathway (21), are 
characterized by abnormal cortical architecture with excessive cell size and tumour-like 
mass effect, such as tuberous sclerosis. 
In 2007, we reported a unique case of a ‘diffuse gangliocytoma’ involving the temporal lobe 
in a patient with late onset epilepsy  which posed such a diagnostic conundrum (45). 
Pathology examination of an MRI visible lesion disclosed diffuse involvement of the white 
matter by nodules of vacuolated ganglion cells; malformations as focal cortical dysplasia 
(FCD), mild malformation of cortical development, nodular heterotopia were diagnoses 
considered in addition to a neuronal tumour.  Recently reports of histologically similar lesions 
have been termed ‘Multinodular and vacuolating neuronal tumours (MVNT)’(7, 17, 24) and 
this entity is now included in the current 2016 WHO classification of CNS tumours as a 
pattern of gangliocytoma but with ‘uncertain class assignment’ (34). Indeed, it has been 
commented that these lesions ‘may even be malformative in nature’ and it is acknowledged 
that further characterization is needed to fully understand their nosological place among 
CNS neoplasms (33).  
In this study, we review the clinical and pathological findings in a series of ten cases of  
MVNT (including the case in our initial report (45)). We explore the cellular differentiation and 
maturation, genetic abnormalities, and potential epileptogenic mechanisms in an aim to 
better explore its delineation between cortical malformation or an epilepsy-associated 
tumour in the context of long-term focal epilepsy.  
 
Methods 
CASE SELECTION 
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Seven cases of MVNT were ascertained from pathology review of all glio-neuronal tumours 
and malformations in the Department of Neuropathology and Epilepsy Society Brain and 
Tissue Bank at UCL. A further three cases of MVNT were included from the Academic 
Medical Centre (Amsterdam, Netherlands), Great Ormond Street Hospital for children, 
(London, UK) and Hospital Pedro Hispano, (Matosinhos, Portugal).  There is ethical approval 
for this study and all surgical patients consented for use of tissue, clinical and MRI data in 
research.  We also included fetal developmental controls (from MRC-Wellcome Trust Human 
Developmental Biology Resource HDBR, UCL), conventional gangliogliomas/low grade 
glioneuronal tumour (WHO grade I), temporal lobe cortex adjacent to hippocampal sclerosis 
with mild malformation of cortical development type II (increased white matter neurones (6, 
32)), and FCD type II cases from epilepsy surgical  patients, as comparative control groups 
for immunohistochemistry (Supplemental Table 1 for details) or genetics studies. 
IMMUNOHISTOCHEMISTRY 
Routine H&E and LFB/CV were performed on sections of all cases using the Leica ST5020 
Autostainer (Leica, Milton Keynes, UK). From all cases we then selected a representative 
block and a panel of immunohistochemistry markers (Table 1) was applied on 5 µm formalin-
fixed, paraffin-embedded brain sections to explore : neuronal differentiation (NeuN, 
neurofilaments, synaptophysin, MAP2), astroglial differentiation (GFAP and GFAPδ), 
oligodendroglial lineage and myelination (Olig2, SMI94/myelin basic protein (MBP)) and 
common glioma mutations (IDH1, ATRX and BRAF V600E). In seven cases with sufficient 
material available, a more extensive immunohistochemistry panel was applied including 
cortical layer specific markers (TBR1, TBR2, OTX1, N200, MAP1B), developmental/stem 
cell markers (CD34, Reelin, PAX6, SOX2, Nestin, DCX, PDGFRβ), interneuronal subsets 
(calbindin, calretinin, parvalbumin, NPY), chloride co-transporters (NKCC1, NKCC2), 
neurodegenerative markers (p62, AT8, APP, mitochondria) and mTOR pathway activation 
(pS6, Ser 240/244 and pS6, Ser 235/236). Either automated immunohistochemistry was 
performed (Bond Max Automated Immunostainer (Leica, Milton Keynes, UK)) or it was 
carried out manually using standard protocols as previously detailed (20) (Table 1).  
NEXT GENERATION SEQUENCING 
Next generation sequencing (NGS) of MVNT was carried out in eight of the nine surgical 
samples (case 7 not sequenced due to lack of availability of frozen tissue and the post 
mortem case 4 failed sequencing due to low quality of DNA). Tumour tissue was manually 
micro dissected from 10 μm tissue sections. DNA was extracted using the BiOstic FFPE 
Tissue DNA Isolation kit (MO BIO, Carlsbad, CA, USA) according to the manufacturer’s 
instructions. NGS was performed using a customised Ion AmpliSeq™ Neurology Panel 
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(ThermoFisher Scientific, Waltham, Massachusetts, USA) for targeted multi-gene 
amplification. This panel consists of the following genes; AKT1, AKT3, ATRX, BRAF, CDK6, 
CIC, CTNNB1, DDX3X, DEPDC5, EZH2, FGFR1, FUBP1, H3F3A, HIST1H3b, HIST1H3c, 
IDH1, IDH2, KDM6A, mTOR, MYB, MYBL1, NPRL2, NPRL3, PIK3CA, PIK3R1, PIK3R2, 
PTCH1, PTEN, SMARCA4, SMARCB1, SMO, SUFU, TP53. Libraries were prepared using 
the Ion AmpliSeq Library Kit 2.0. The Ion PGM Hi-Q Kit and Ion Chef Instrument were used 
for emulsion PCR and template preparation. The Ion PGM Hi-Q sequencing Kit with the Ion 
318 V2 Chip and Personal Genome Machine were used as sequencing platforms. DNA input 
was up to 20 ng, which was measured by the Qubit 3.0 Fluorometer. Up to 20 specimens 
were barcoded using the IonXpress Barcode Adapters for each Ion 318 V2 Chip. A mean 
coverage of 1500X per amplicon was established, and the data was analyzed using JSI 
SeqNext (JSI Medisys, Ettenheim, Germany). Of note, the selected sequencing panel was 
developed to identify most mutations in the genes studied. However, not all exons of each 
gene were analysed, thus there is  a risk of undetected mutations in tumor suppressor 
genes. Gene duplications were not detected, and the sequence analysis of MVNT were 
compared to 22 samples with FCD type II and 8 glioneuronal tumours. 
CLINICAL DATA AND MRI 
The clinical notes from each case were reviewed for presenting neurological symptoms and 
updated post-operative information. MRI had been carried out in different centres using 
different MRI sequences and protocols. All available pre-operative MRI scans of surgical 
cases (Case 1,2,5,6,8 and reports in the remainder) were reviewed by a neuroradiologist  
(HRJ) in addition to post-operative MRI findings of any disease progression/recurrence. 
Results 
Of the ten cases with MVNT, nine were surgical resections carried out for treatment of 
epilepsy, and a further case was identified at post-mortem as an incidental finding (Table 2). 
One surgical case was previously reported as an unusual  gangliocytoma (Case 1) (45), and 
two further surgical cases were initially diagnosed as a gangliocytoma and a demyelinating 
condition (Cases 2 and 3 ) following histopathological assessment; the PM case was 
diagnosed as subcortical grey matter heterotopia (Case 4). The remaining six surgical cases 
(all reported since 2014) were recognized as MVNT.  
CLINICAL FEATURES 
Six of the ten cases were females. The mean age at seizure onset was 29.7 years based on 
information available (Table 2) with a mean age at surgery of 45 years (range 6 to 67 years). 
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The single post-mortem case was a 62 year old male without a clinical diagnosis of epilepsy. 
In five surgical cases, the lesions primarily involved the temporal lobe, and mesial structures 
(hippocampus, amygdala or parahippocampal gyrus); the post-mortem lesion involved the 
occipital lobe. Clinical outcomes were available up to 14 years post-operatively, however 
four cases were recently operated with less than two years of follow- up. Only one patient 
did not become seizure-free post-operatively, and no case has documented lesion 
progression on MRI, even in cases with partial resections (Table 2).  
NEUROIMAGING FEATURES 
Salient MRI features common to all cases included poorly defined regions of signal 
abnormality in the temporal lobe, typically hypo-intense on T1 with hyperintensity on T2 and 
FLAIR sequences, involving the cortex and straddling the subcortical region with more clear 
involvement of the adjacent white matter in some cases (Figure 1). A vague, corrugated 
contour was apparent in some but without clear nodularity or cystic change. Although the 
extent of the abnormality varied between cases, there was no or minimal mass effect 
associated with these lesions. There was no enhancement or restricted diffusion where 
investigated. Clear involvement of the hippocampus was apparent in Cases 1, 2, 8 and 9 
(Figure 1a,b). There were no progressive changes on serial images in the pre-operative 
period, in one case with six interval MRI studies (Case 5, Figure 1c,d) and over review 
periods of up to eight years (Case 1, Figure 1a). Low grade glioma was considered the likely 
diagnosis or, less likely cortical dysplasia, based on imaging features. None of the lesions 
showed progressive changes during the post-operative period (Table 2). 
NEUROPATHOLOGY FINDINGS 
Macroscopic abnormalities noted in fixed, resected lobectomy specimens included focal  
translucency or cavitation of the subcortical white matter in the gyral cores of the temporal 
lobe white matter (Figure 2a) or with plaque-like nodules or islands of grey discolouration 
(Figure 2e). In the post-mortem specimen, nodules of grey matter were noted in the 
subcortical white matter of the right occipital lobe only.  
Histological examination at low magnification in larger resections confirmed islands or 
nodules, predominantly located in the subcortical white matter or ‘sitting’ in the deeper 
cortical layers. Coalescing or abutting nodular islands (Figure 2i) as well as areas of more 
diffuse subcortical white matter involvement (Figure 2c) were observed. The architecture and 
extent of the white matter component at low power was best appreciated by reduced myelin 
on myelin stained sections (LFB/CV or SMI94/MPB) (Figure 2b, c, d, i) and for the cortical 
component, reduced synaptophysin (Figure 2f).  In regions bearing cortical nodules, the 
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laminar cyto-architecture and myelo-architecture of the cortex was otherwise undisturbed.  
The nodules were composed of large cells with overall gangliocytic morphology, prominent 
nucleoli with frequent cytoplasmic vacuolation or peri-cellular vacuolation (Figure 2j). Cells 
with more eosinophilic cytoplasm and rarer bi-nucleate cells were present (Figure2k). There 
was minimal clustering and no orientation of vacuolated cells (VC) within nodules but 
arrangements alongside vessels were noted in one case (Figure 2l). In addition to the 
predominant VC, smaller oligo-like glial cells were intermingled, but without satellitosis. The 
impression in some nodules was of diminished cellularity compared to adjacent white matter 
(Figure 2m) although in other cases (Case 7) regions of diffuse hypercellularity were noted. 
Mitotic activity and significant pleomorphism was lacking. Rosenthal fibres or calcification 
were not present and prominent perivascular infiltrates were noted in four cases.  
In five cases, the involvement of the hippocampus was present, with islands of VC in the 
white matter underlying the subiculum (Figure 2d), CA1 and as well as parahippocampal 
gyrus white matter and amygdala. In Case 8, the mesial temporal component showed 
cytology more typical for ganglioglioma with dysmorphic gangliod cells, eosinophilic granular 
bodies (EGBs)  (Figure 2n) and nodules of spindled astroglial cells,  even though the 
temporal lobe  component had the typical appearances of MVNT (Figure 2h) ; this suggested 
a tumour with hyrbrid features. Hippocampal sclerosis was also noted in three cases.  
NEURONAL DIFFERENTIATION 
Immunolabelling using the mature neuronal marker, NeuN, was weak or negative (Figure 3a) 
in VC, in keeping with previous reports (7, 24) but we confirmed consistent, strong 
expression for non-phosphorylated neurofilament (SMI32) in VC in all cases (Figure 3b). 
Other neurofilament antibodies (Table 1), including phosphorylated neurofilament (SMI31), 
neurofilament cocktail and N200 labelled only occasional axons traversing through nodules 
but VC were mainly negative. MAP2 highlighted VC and dendrites (Figure 2h, 3c) and a 
proportion of the small multipolar cells in nodules. In Cases 3 and 4, the MAP2 labelling was 
weaker in VC compared to other overlying cortical neurones. Despite an overall reduction of 
synaptophysin expression in the nodules (Figure 3e), imparting a ‘moth-eaten’ appearance 
to the cortical-white matter border at low magnification (Figure 2f); a proportion of VC 
showed weak cytoplasmic labelling in all cases (Figure 3d). In Case 8 with a focal 
ganglioglioma component, stronger synaptophysin labelling of atypical ganglion cells was 
noted compared to the VC. 
CORTICAL LAYER DIFFERENTIATION MARKERS 
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Application of cortical layer and neuronal linage markers revealed variable labelling of VC for 
TBR1; a proportion of VC in four of eight MNVN showed strong nuclear positivity (Figure 3f) 
while in other cases, VC were weak or negative. The overlying cortex showed TBR1 nuclear 
labelling of neuronal cells in all cortical layers. In Case 8 with the ganglioglioma component, 
dysplastic neurons were negative with TBR1. There was no labelling of VC for TBR2 in any 
case. Intense cytoplasmic labelling of  VC for OTX1 was noted in all cases apart from the 
post-mortem case (Figure 3g) ; in comparison the overlying cortex and normal white matter 
was negative with this marker in keeping with previous reports (20). OTX1, therefore, 
appeared a specific marker to distinguish VC from normal interstitial neurones in the white 
matter as well as delineating the extent of the MVNT. With MAP1b, we also observed 
intense cytoplasmic labelling of the VC and their dendritic like processes in all cases (Figure 
3h) in addition to labelling of pyramidal cells of normal morphology in layers II, III and V of 
the overlying cortex. 
GLIAL LINEAGE MARKERS 
GFAP accentuated variable proportions of small, multipolar astroglial cells and processes in 
the lesion typically merging with a denser gliosis in the surrounding white matter (Figure 3i, 
bottom inset). In Case 8 with a ganglioglioma component, a more prominent GFAP-positive 
glial tumour component was confirmed.  GFAPδ showed restricted expression in  MVNT, 
localising to the nodules and diffuse components at low magnification (Figure 3i), labelling 
small multipolar glial cells in proximity to VC and sometimes enveloping them (Figure 3i, top 
inset). In keeping with previous reports (7, 24) VC showed strong nuclear labelling for OLIG2 
(Figure 3j); a proportion of the smaller glial cells associated with the lesion were OLIG2-
positive. NG2 and PDGFRα immunomarkers did not show any consistent labelling of the 
surgical cases or post-mortem tissue. However PDGFRβ, which labels both pericytes and 
NG2/oligodendroglial progenitor cells (18, 55), small multipolar cells within in the nodules 
away from vessels as well as in adjacent tissue were noted (Figure 3k) ; the large VC were 
negative with PDGFRβ. MBP (SMI94) showed striking abnormalities, correlating with overall 
reduction of myelinated fibres in the lesion as described above (Figure 2c,i). In addition, 
cytoplasmic membranous or granular labelling of VC was noted for MBP (Figure 3l) and the 
rims of empty vacuoles also highlighted.  
NEURODEVELOPMENTAL AND INTERNEURONAL MARKERS 
VC were largely negative for reelin, and cells with the morphology of Cajal-Retzius cells 
were not seen within the nodules, although they were present in the overlying cortex. VC 
were also mainly negative with PAX6 which showed nuclear labelling of a proportion small 
cells in the vicinity of the nodules (Figure 4a). Consistent cytoplasmic or membranous 
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labelling of VC in MVNT with SOX2 was seen in all cases studied, demarcating the nodular 
and serpiginous islands of the lesion at low magnification (Figure 4b). CD34-positive 
multipolar cells were present in all cases, ranging from very occasional cells (Case 2) to 
extensive labelling (in Cases 7,8) (Figure 4c). With DCX and nestin, only occasional VC 
were positive (Figure 4d,e), both markers showed more prominent labelling of small cells 
associated within the lesion.  Nestin also highlighted a population of bipolar cells with long 
processes in some nodules (Figure 4e ; inset). Calbindin, calretinin, parvalbumin and NPY 
(Figure 4f) showed a normal morphology and distribution of interneurons in adjacent cortex 
and white matter. VC were generally negative with these markers, apart from one case 
(Case 3) which showed PV expression in VC (Figure 4g). Interneurons of normal 
morphology and axonal networks were also intermingled in the MVNT, although there was 
an impression for reduced numbers compared to adjacent tissue in some cases (Figure 2g, 
4f). KCC1 showed strong cytoplasmic labelling of VC (Figure 4h) but labelling with KCC2 
was less distinct.  
NEURODEGENERATIVE, MTOR PATHWAY AND CELL CYCLE MARKERS 
In none of the surgical cases were tangles noted in VC, and AT8 for phosphorylated-tau was 
virtually negative.  In the post-mortem case with a neuropathology diagnosis of AD, the 
cortical nodules of the MVNT, in fact, were strikingly spared from tau accumulation 
compared to the adjacent cortex (Figure 4i) suggesting late acquisition of degenerative 
changes. VC showed cytoplasmic labelling with APP and intense labelling for p62 (Figure 4j) 
and anti- mitochondrial antibodies (Figure 4k) compared to adjacent cortical and white 
matter neurones. With mTOR pathway antibodies, anti-pS6 (ser235/236 and ser240/244),  
minimal labelling of VC was observed across all cases ; occasional  dot-like positivity in the 
cytoplasm was noted in some VC, in contrast to the intense labelling of scattered pyramidal 
cells in the overlying cortex (Figure 4l ; insets)  and the dysmorphic neurons of the 
ganglioglioma component of Case 8. However, strong cytoplasmic labelling for pS6 
antibodies of small glial-like cells associated with the lesional nodules was noted (Figure 4l). 
A high proportion of VC showed nuclear labelling with MCM2 (Figure 4m) in contrast to Ki67 
labelling which was virtually absent in VC, but noted mainly in small cells and inflammatory 
cells ( overall <5%). In all MVNT cases, immunohistochemistry for mutant IDH1, ATRX and 
BRAF V600E mutations were negative. 
COMPARISON OF MVNT TO CONTROLS GROUPS 
In ganglioglioma controls, Tbr1 nuclear labelling of dysmorphic neurons was noted in one 
case (Supplementary Figure 1a); a variable proportion also showed cytoplasmic OTX1 
positive labelling (Supplementary Figure 1b) but more consistent labelling was observed with 
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SOX2 (Supplementary Figure 1c).  There was little evidence of nuclear labelling of 
gangliogliomas for OLIG2 was seen (Supplementary Figure 1d) but strong labelling with 
calbindin as previously noted (Supplementary Figure 1e)(62) and also with p62 as previously 
reported (43). Dysmorphic cells in ganglioglioma infrequently labelled with MCM2 in contrast 
to MVNT (Supplementary Figure 1f). In temporal lobe white matter with mild MCD type II, 
strong Tbr1 labelling of interstitial white matter neurons was noted (Supplemental Figure 1g) 
but not OTX1 (Supplemental Figure 1h), and rare positive neurones were observed with 
SOX2 (Supplementary Figure 1i) or Mapb1b; OLIG2 was restricted to mature-appearing 
oligodendroglia (Supplementary Figure 1j). pS6 expression in TLE white matter showed 
occasional labelling of white matter neurons  and small glial cells (Supplementary Figure 1k) 
but no labelling with KCC1 (Supplementary Figure 1l). In fetal developmental controls, strong 
labelling, primarily in the periventricular germinal matrix, was confirmed with Tbr2, OTX1 and 
SOX2 (Supplementary Figure 1m,n,o).  
MOLECULAR GENETICS 
Of the 33 genes studied, single mutations in SUFU was identified in Case 2, and in EZH2 in 
Case 8 (Table 3). No mutations in MTOR, DEPDC5, FGFR1, MYB or BRAF were identified 
in any MVNT. Recurring synonymous SNPs in DEPDC5, SMO and TP53 were present in all 
surgical MVNT tested, with less frequent synonymous SNPs occurring in some MVNT only  
(Table 3 and Supplementary Table 2). We compared the MVNT to FCD type II (22 samples) 
and 8 glioneuronal tumours; SUFU mutation was present in one FCD type II case but not in 
other glioneuronal tumours. Identical DEPDC5 and SMO E3 SNP also occurred in all FCD 
type II samples and the majority of glioneuronal tumours, while the other common SNPs did 
not occur in all FCD or glioneuronal tumours. Of note, a NPRL3 variant was found in 5/8 
MVNT and 90% of FCD but none of the glioneuronal tumours.  The genetic and 
immunohistochemistry findings in MVNT are summarised and compared to findings in 
controls as well as published data on related tumours and malformations associated with 
long-term epilepsy in Supplementary Table 3. 
 
Discussion 
In 2014, Huse et al., described ten cases of a novel low-grade neuronal lesion, mainly 
associated with epilepsy and coined the term ‘multinodular and vacuolating neuronal tumour’ 
(24). Subsequently, five more cases have been reported (7, 17, 39, 68), and this new entity 
was added to the list of patterns of CNS neoplasms in the recently revised 2016 WHO 
classification (33).  We present the pathology in a further ten cases, including a case 
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previously reported in 2007 as an unusual vacuolated diffuse gangliocytoma (45). Our 
findings confirm their indolent behaviour, and predominant involvement of the temporal lobe 
presenting with late onset of epilepsy, typically in adulthood. We have extended 
investigations into their neoplastic versus malformative nature, cell lineage and potential 
mechanisms of epileptogenesis through the application of immunohistochemistry and NGS. 
It remains possible that MVNT align more with developmental anomalies than true 
neoplasms. Although these lesions are rare, it is probable they have been previously 
unrecognised, being misdiagnosed  as demyelinating conditions (7) or other more common 
lesions encountered in epilepsy series (as listed in Supplementary Table 3) with which they 
share histological similarities. 
NEOPLASIA OR MALFORMATION 
MVNT has been grouped as a pattern of gangliocytoma in the revised 2016 WHO 
classification of CNS tumours. Features in common with other low-grade epilepsy-
associated tumours (LEATs)(57) include a predilection for the  temporal lobe, MRI 
characteristics (39, 68), frequent CD34-positivity, and a mixed neuronal and glial 
composition. We include the first report of a case with mixed features of both MVNT and 
conventional ganglioglioma in support of a potential common origin, and we identified two 
cases with novel mutations in SUFU and EZH2, although these mutations are of uncertain 
significance. 
As previously noted (24, 45), some features of MVNT align more with a malformation of 
cortical development or dysplasia than a neoplasm, supported by evidence in this current 
study. This includes (i) the lack of any growth on serial MRI or reported regrowth, even 
following incomplete resection, (ii) no overt increase in cellularity or conspicuous mitotic 
activity, (iii) lack of expansive or infiltrative growth patterns with nodules ‘sitting’ in an 
undisturbed laminar cortex, (iv) comparable localisations in deep cortex/subcortical region in 
reported cases, (v) retained expression of immature, developmentally regulated proteins as 
SOX2, TBR1, OTX1, KCC1 and GFAP∂, (vi) absence of any of the known genetic 
abnormalities of LEATs following NGS, including BRAF V600E, MYB and FGFR1 mutations 
(15, 25, 42, 44, 47, 50), and (vii) NGS in the present study showing recurring synonymous 
SNPs in SMO and DEPDC5 in common with cortical dysplasia (FCD IIB) and NPRL3 SNPs 
noted frequently in MNVT and FCD but not other glioneuronal tumours. Copy number 
variations in SMO a receptor in the Shh pathway have been recently shown in hypothalamic 
hamartoma associated with gelastic seizures (22) and DEPDC5 and NPRL3 mutations 
reported in FCDII (5, 56).  Further histological features in common between MVNT and FCD 
IIB include the striking hypomyelination of involved white matter which may relate to 
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deficiencies in oligodendroglial lineages (46, 51, 55, 70). Also the distinctive MCM2 positivity 
of VC is reminiscent of balloon cells in  FCD (61). MCM2 labelling of balloon cells is 
considered not to reflect neoplastic cell proliferation, but cell cycle arrest in a pathological 
progenitor cell type (60, 69).  
LINEAGE AND MATURITY OF VACUOLATING CELLS 
Previous reports have emphasised the preferential expression of immature markers, 
including HuC/HuD, compared to mature neuronal markers as NeuN in the lesional cells (7, 
17, 28, 39, 68). Our study supported evidence for mature neuronal differentiation of VC with 
labelling for some anti-neurofilament antibodies (particularly SMI32) although NeuN was 
typically weak or negative. Expression of DCX, a microtubule-associated protein (MAP) 
expressed in migrating neuronal precursors was previously reported in a MVNT (39) but not 
consistently expressed in our series. We noted however more robust expression with 
MAP1b, which is highly developmentally regulated but normally retained  in neurogenic 
areas in the adult brain or regions undergoing structural plasticity (66). Strong expression of 
nodules for alpha-internexin, an intermediate neurofilament expressed in neuroblasts has 
also been previously shown in MVNT (39, 68), but more variable expression of nestin (39, 
68) in line with our observations. We also noted intense expression of stem cell markers 
SOX2 and CD34, which has been consistently reported in CNS tumours, LEATS and FCD 
(35, 41, 57). 
Immunohistochemistry for OTX1 showed striking labelling of VC, highlighting the subcortical 
extent of the MVNT. In murine cortex, homeobox gene OTX1 is expressed in mid to late 
gestation during development primarily in early migrating neurones destined for deeper 
cortical  layers V and VI (8) particularly in the temporal lobe (3). OTX1 null mice show 
temporal cortical thinning (12) and spontaneous seizures (3). In the developing human brain, 
OTX1 is strongly expressed in the forebrain and proliferative layers of the neocortical 
precursors (30) as we also observed. In mature human cortex, OTX1 has been shown to be 
expressed in layer V pyramidal neurones (29, 38) as well as immature cells in FCD I and II 
(20, 29). The consistent expression of OTX1 in MVNT, appeared more pronounced than 
observed in ganglioglioma or the dysmorphic neurones of FCD (20) and could suggest that 
VC are derived from incomplete maturation or migration of progenitors destined for the 
deeper cortical layers. This could be one explanation for the predominant location of MVNT 
in deeper cortex compared to outer cortical layers. Focal TBR1 expression in VC is further 
support for their derivation from radial migrating progenitor cells or possibly subplate 
remnants (16).   
GLIAL DIFFERENTIATION AND MYELINATION 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
GFAP in MVNT highlighted a variable reactive glial component merging an adjacent gliotic 
parenchyma, in keeping with previous observations (7, 24). However, using isoform GFAPδ 
we observed distinct populations of intra-lesional cells as evidence for a glial-cell component 
associated with MVNT.  GFAPδ is normally restricted to glia residing in stem cell niches 
including  the subventricular zone (65) as well as some malformations (29, 36) and astrocytic 
tumours (11) but with a less consistent expression in reactive gliosis (27). Furthermore, 
preferential labelling of smaller intralesional cells, rather than the VC, for pS6, PDGFRβ, 
PAX6 and nestin also argues for a mixed cellular  composition in MVNT. Uniform labelling of 
both the VC as well as the smaller cells in MVNT for OLIG2 has been previously reported (7, 
17, 24, 39, 68) and confirmed in our series. This transcription factor has a recognised 
oncogenic role in glioma growth (64), however in MVNT OLIG2 expression is noted in the 
context of overall reduced myelination and labelling of VC for myelin basic protein. One 
further hypothesis is that VC originate from OLIG2-positive oligodendroglial progenitor cell 
types (OPC) (23) with developmentally arrested or partial maturation, resulting in defective 
myelination (9) and even aberrant neuronal differentiation (19). Indeed an occasionally 
observation in MVNT in this and previous reports (24) has been clustering of VC along 
vessels, reminiscent of developmental migration patterns of OPC (63). Recent description of  
a novel subtype of mild malformation of cortical development in frontal lobe epilepsy, 
associated  with increased OLIG2 cells in the deep cortical layers and superficial white 
matter with myelin loss also draws comparison with MVNT (52).  
NEUROIMAGING, CLINICAL PRESENTATION  
Characteristic appearances reported in MRI of MVNT include multi-nodularity (7, 68), 
satellite nodules away from a main lesion (Nagaishi, Yokoo et al. 2015), hyperintensity on T2 
and FLAIR and preferential involvement of the grey-white matter junction following gyral 
contours, sometimes with a corrugated outer margin (Fukushima, Yoshida et al. 2015). 
Combinations of these imaging features may enable the future distinction of MVNT pre-
operatively from other LEATs, gliomas and FCD. Interval MRI has also shown a lack of 
growth over 18 months (7, 24) as also supported by longer pre-operative observational 
periods in this series.  
From the 24 cases of MVNT reported (7, 17, 24, 68), the mean age at the time of surgery is 
44.6 years. Although epilepsy was present in all our surgical samples it has been 
documented in just less than half of reported cases with an average age of onset of seizures 
of around 30 years. However, we include the youngest case, operated at six years 
confirming MVNT may be encountered in the paediatric age-group. MVNT predominate in 
the temporal lobe with 18 of the 24 reported cases arising here, with a mesial component in 
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eleven (7, 17, 24, 39, 68). ‘Ribbon-like’ extensions of the tumour along the hippocampal 
formation and subiculum have been previously described, (68) and was striking in five of our 
cases which could potentially enhance hippocampal epileptogenicity, although presence of 
associated hippocampal sclerosis is variable. 
EPILEPTOGENSIS AND NEURODEGENERATION 
An older age at manifestation of epilepsy in MVNT compared to other epileptogenic lesions 
could be explained by their predominant subcortical location with limited cortical connectivity 
or relative functional inactivity. We explored acquisition of neurodegenerative changes in the 
VC for several reasons :  accumulation of hyperphosphorylated tau/neurofibrillary tangle 
formation and p62 accumulation occurs early in dysmorphic neurones of FCD and 
ganglioglioma (26, 43, 54), indicating an enhanced vulnerability to degeneration. This could 
be an effect of mTOR over-activity (43), that we demonstrated in MNVT with pS6 labelling,  
or increased neuronal excitability (67). By contrast in MVNT, although p62 was prominent, 
there was a striking absence of tangles or phosphorylated tau with AT8 
immunohistochemistry. Indeed, even in the oldest post-mortem case with high Braak stage 
AD, sparing of VC and nodules from tau accumulation was noted. Possible explanations 
include  a functional disconnection of MVNT from the  adjacent cortex preventing tau 
seeding (31)  or indirectly it could reflect reduced excitability of VC if tau phosphorylation is 
activity driven.  
We explored other potential pro-epileptogenic cellular alterations in MVNT as previously 
investigated in related pathologies (2, 53, 58, 59) (Supplementary table 3). We identified 
some evidence for cation-chloride cotransporter (KCC1/KCC2) imbalances in VC in keeping 
with cell immaturity (37, 49), reductions of inhibitory interneurons within lesions, immature 
astroglia (48), focal inflammation (14) as pro-epileptogenic cellular alterations, that could 
operate in MVNT but warrant further in-depth investigation. 
In conclusion, MVNT are uncommon but distinct lesions mainly presenting in the temporal 
lobe in older patients with seizures. They appear indolent and lack any of the common 
mutations identified in LEATS or morphologically similar malformations. Our studies support 
a mixed cellular composition and expression of a range of immature markers which could 
indicate an origin from an aberrant progenitor cell type during development.  
Note added in Proof 
Since submission of this study, further cases and series have been reported, attesting to the 
indolent nature of MNVT (1, 4, 10, 40). 
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Figure Legends 
Figure 1 Neuroimaging Features Of Multinodular And Vacuolating Neuronal Tumour.   
(A) Case 1 (as reported in the original case report(45)) showing marked signal change in the left temporal lobe, 
parahippocampal gyrus and  hippocampus on coronal FLAIR but with minimal mass effect; little change was 
noted over 8 years. (B) Case 8. Abnormality was observed in the right mesial temporal region with 
hyperintensity on coronal FLAIR sequence. (C) Case 5. Initial FLAIR MRI sequences at presentation highlighted a 
lesion in the right posterior temporal lobe as a diffuse cortical abnormality,  which did not show significant 
growth on MRI, as shown in  (D)  at 21 months following the initial scan.(E) Case 6 shown with T2 and (F)  FLAIR 
sequences, highlighting a hyperintense abnormality and the cortical, white matter interface in the  left 
temporal lobe.  
 
Figure 2. Macroscopic and Low Power Histological Features Of Multinodular And Vacuolating Neuronal 
Tumours (MVNT) 
(A) Macroscopic features of the temporal lobe specimen from Case 1 show areas of breakdown/cavitation in 
the gyral cores and focal translucency of the white matter. (B) Luxol fast blue/cresyl violet stained section from 
Case 1 confirms lack of myelin in some gyral cores (arrow) and pale hypomyelinated nodules at the cortical 
white matter junction extending into the white matter (arrowhead). (C) SMI94/myelin basic protein confirms 
diffuse regions of poor myelination (arrow) and nodular like patterns (arrowhead) in the white matter in Case 
1. (D) Abnormal nodular islands of cells in the subiculum in Case 1, present on both sides of the pyramidal cell 
layer, although predominantly in the subcortical region (arrowhead). (E) Macroscopic appearance of fixed 5 
mm sections of the temporal lobe in  Case  2 shows islands of grey tissue in the white matter of the inferior 
medial part of the specimen with an overlying normal-appearing  cortex. (F) Synaptophysin labelling in Case 4 
highlights the nodules encroaching on the deep cortical layers with reduced labelling compared to the 
adjacent cortex. (G) Neuropeptide Y in Case 4 at low power shows reduction of labelling within the cortical 
nodules compared to adjacent cortex (arrowheads). (H) MAP2 staining in Case 8 in the temporal cortex shows 
variable patterns with reduced MAP2 labelling in some nodules (arrowhead) compared to others (arrows). (I) 
Myelin basic protein staining (SMI94) in Case 4 highlights abutting, myelin-poor nodules. (J) The abnormal 
white matter regions are populated by single scattered cells with a neuronal/ganglion cell appearance and 
prominent vacuolation of the cytoplasm or vacuoles surrounding the cells. (K)  Occasional binucleated cells 
were seen (arrowhead) and cells with more eosinophilic cytoplasm were observed in MVNT after H&E staining. 
(L)  In some cases alignment of the atypical cells along vessels was noted in the nodules (Case 4). (M). The 
border (arrowhead) between  a nodule in MVNT(top half of figure) and the white matter (lower half of figure) 
on cresyl violet  stain gives the impression of overall reduced cellularity, particularly for small oligodendroglial-
like cells in the nodules, compared to the adjacent white matter. (N). In Case 8, a focal area in the mesial 
temporal lobe showed more typical appearances of a ganglioglioma, with dysplastic neurones and eosinophilic 
granular bodies.  Bar = 1cm for macroscopic images in A and E; = 3mm for B, C, D, F, G, H ; =0.5mm for I  ; = 100 
microns for J, L, M, N and =50 microns for K (approximate based on original magnifications). 
 
Figure 3. Neuronal And Glial Marker Expression In Vacuolated Cells (VC) 
(A) NeuN staining showed labelling of normal interstitial neurons in the white matter, but the vacuolated cells 
(VC) were typically weak or more often negative (arrowheads). Labelling of VC with (B) neurofilament, (C) 
MAP2, (D) synaptophysin is shown. (E) Overall,  reduced labelling with synaptophysin was observed in the 
cortical nodules. (F) TBR1 neuronal lineage marker shows nuclear labelling of t VC and strong cytoplasmic 
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labelling noted with (G) OTX and (H) MAP1b. (I) GFAPδ highlighted small glial cells primarily in the nodules at 
low power  ; inset  (top) multipolar GFAPδ cells in proximity to VC), inset (bottom) GFAP conventional isoform 
shows opposite pattern with more extensive labelling of the gliosis around the lesions.  (J) Nuclear labelling of 
VC with OLIG2 whereas (K) PDGFRbeta highlighted small multipolar cells in the nodules but not the VC. (L) 
SMI94 for myelin basic protein, as well as demonstrating the diminished myelination in the white matter 
nodules (see also Figure 2), also showed membranous labelling of the VC (arrow).Bar = 80 microns (A, C, D, F, 
G, H, J) = 40 microns (I) and 140 microns (B, K) and 200 microns (E and I) (approximate, based on original 
magnifications). 
 
Figure 4. Immature And Interneuronal Markers In Multinodular And Vacuolating Neuronal Tumour 
(A) PAX6 was negative in vacuolated cells (VC) but labelled nuclei of small cells within the lesion. (B) SOX2 
showed strong labelling of the nodules and VC  highlighting the regions of involvement at low magnification (C) 
CD34 showed variation in the staining between cases, but as shown here in Case 5, prominent multipolar cells 
and processes were evident in the regions with VC. (D) Occasional doublecortin positive (DCX) VC were seen. 
(E) VC were mainly nestin negative but occasional positive cells were seen (inset left). Small nestin expressing 
cells were noted in the lesion and occasional bipolar cell (inset right). (F) NPY showed reduced labelling in 
nodules of one MVNT (case 4), arrows showing the edge of the nodule; NPY staining labelled scattered 
interneurons in the lesion of normal morphology but the VC were negative (arrowed in inset). (G) Case 3 
showing strong labelling of VC for parvalbumin. (H) Cationic chloride transporter ((N/KCC1) with distinct 
cytoplasmic labelling of the VC. (I) AT8 labelling for phosphorylated tau in Case 4 with Alzheimer’s disease 
pathology, and dense cortical tau in tangles and threads showed a marked sparing of the VC and nodules on 
MVNT for tau accumulation (arrows). (J) VC were strongly positive with p62 and (K) anti-mitochondrial 
antibodies. (L) VC were not positive with both pS6 markers pS6 Ser240/244 (shown here) and pS6 Ser 235/236, 
apart from occasional dot -ike positivity in the cytoplasm of uncertain significance (insert left); in contrast the 
overlying cortex (insert left) showed strong scattered neuronal positivity. (M) A high proportion of VC were 
MCM2 nuclear positive.  Bar = 50 microns (A,D,E,G,H,K,L,M) = 20 microns (B,I,F,J) (approximate based on 
original magnifications). 
 
 
Supplemental Figure 1 : Comparative Labelling In Ganglioglioma Cases,  TLE /Temporal Lobe In Temporal Lobe 
Epilepsy With Increased White Matter Neurones (Equivalent To Mild MCD/Malformation Of Cortical 
Development Typ  II) And Developmental Controls Of 13 Gestational Weeks. 
(A) Tbr1 in gangliogliomas showed strong nuclear labelling in two cases as shown, but negative labelling in two 
further cases (not shown). (B) OTX1 in ganglioglioma showed cytoplasmic positivity of dysmorphic neurons in a 
proportion of cases. (C)  SOX2 in gangliogliomas showed  granular cytoplasmic (or peripheral  cytoplasmic 
staining) of dysplastic ganglion cells which was variable between cases. (D) OLIG2 was negative in the atypical 
neuronal cells of gangliogliomas or showed cytoplasmic granular staining but nuclear labelling was not a 
feature; (inset) PDGFRβ did not label the atypical ganglion cells. (E) Calbindin showed strong labelling of the 
tumour and parenchyma with a sharp border with adjacent tissue and intense labelling of dysmorphic 
neuronal cells (inset). (F) MCM2 labelling in gangliogliomas highlighted inflammatory cell component with 
variable nuclear positivity in a small proportion of the ganglion cells. (G) TBR1 showed labelling of white matter 
neurons in mild MCD. (H) There was no labelling of OTX1 in the white matter neurons with OTX1 in mild MCD 
and weak cytoplasmic labelling of small glial cells. (I) In mild MCD, occasional weak cytoplasmic labelling of the 
single white matter neurons for SOX2 was noted. (J) In mild MCD, the neuronal cells were not OLIG2 positive 
and only labelling of the small oligodendroglial cells seen. (K) phosphor-S6 labelling in mild MCD showed 
occasional labelling of the single white matter neurons and small glial cells and (L) KCC1 did not label the white 
matter neurons in Mild MCD. (M) TBR2 in fetal cortex showed labelling of immature cells in the germinal 
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matrix and in the periventricular zone and developing white matter. (N) OTX1 in developmental controls 
showed a strong, predominantly peripheral ring of cytoplasmic labelling of the germinal matrix cells. (O) With 
SOX2 strong labelling of primitive cells in the germinal matrix was seen.  Bar = 50 microns 
(A,B,C,D,F,H,I,J,K,L,M,N,O); =100 microns in E and 200 microns on G (approximate based on original 
magnifications). 
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GROUP Antibody (source) Epitope/labelling pattern in normal cortex Pre-treatment, 
Antibody dilution 
(mins, temperature) 
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MATURE 
NEURONAL 
MARKERS 
NeuN  (EMD) Neuronal nuclear antigen / neuronal nuclei and cytoplasm ER1, 1:2000 (20, RT) 
SMI32 (Sternberger) Neurofilament (non-phosphorylated 200 kDa protein)/ 
axons and some pyramidal cell bodies  
1:500 (20, RT) 
SMI31 (Sternberger)  Neurofilament (phosphorylated 200 kDa  protein)/axons  1:5000 (20, RT) 
Synatophysin 
(DAKO) 
Synaptic protein / synaptic vesicles ER2, 1:100 (20, RT) 
NFc (DAKO) Neurofilament cocktail  1:500 (20, RT) 
MAP2 (Sigma) Microtubule associated protein / neuronal cytoplasm and 
processes 
H-3301, 1:1500 (60, 
RT) 
CORTICAL 
LAYER 
NEURONAL 
MARKERS* 
TBR1 (Abcam)  T-box brain protein/ nuclei marker for cortical neurones 
derived from intermediate progenitor cells (IPC) 
H-3301, 1:400 (ov, 
4ºC) 
TBR2 (EMD) T-box brain protein/ nuclei marker for basal progenitor 
cells 
H-3301, 1:2500 (ov, 
4ºC) 
OTX1 (Abcam) Orthodendicle homolog 1 / expressed in the nuclei of a 
subset of layer V/VI projection neurones. 
H-3301, 1:100 (ov, 
4ºC) 
N200 (Sigma) Neurofilament 200/ projection neurones H-3301, 1:3000 (60, 
RT) 
MAP1B (Abcam) Microtubule associated protein 1B/ earliest MAP 
expressed in development; in subset of layer V neurones in 
fetal cortex.  
H-3301, 1:2500 (ov, 
4ºC) 
ASTROGLIAL GFAP (DAKO) GFAP / astrocytes ENZ1, 1:2500 (20, RT) 
GFAP delta (EMD) GFAP isoform, developmental regulation/ subset of 
astrocytes, stem cells 
H-3301, 1:5000 
(48hrs, 4ºC) 
OLIGO- 
DENDRO 
GLIAL/ 
MYELIN 
OLIG2 (EMD) Oligodendroglia lineage transcription factor SC, 1:400 (ov, 4ºC) 
SMI94 (Sternberger) Myelin basic protein ENZ1, 1:2000 (20, RT) 
STEM CELL 
/DEVELOP-
MENTAL* 
Reelin (EMD) Extracellular matrix protein / expressed in Cajal Retzius 
cells in cortical development 
H-3300, 1:6000 (ov, 
4ºC) 
PAX6 (Santa Cruz Bio.) paired-box protein; nuclei  H-3300, 1:100 (ov, 
4ºC) 
PDGFR beta 
(Abcam) 
Platelet derived growth factor receptor beta:  NG2/ 
oligodendroglial precursor  cell types
≠
 
H-3300, 1 : 1000 (ov, 
4ºC) 
SOX2 (EMD) sex-determining region Y-box 2/ progenitor cells H-3300, 1:200 (ov, 
4ºC) 
CD34 (DAKO) Stem cell marker/ endothelial cells 1:50 (20, RT) 
Nestin (Abcam) Intermediate filament ; developmentally regulated/ 
expressed in stem cells and radial glial 
H-3300, 1:1000  (ov, 
4ºC) 
Doublecortin (Cell 
Signaling Tech.) 
Developmentally regulated neuronal microtubule 
associated protein/ neuroblasts 
SC, 1:250 (ov, 4ºC) 
INTER-
NEURONAL* 
Calbindin (Swant) Calcium binding protein/ interneuronal marker H-3300, 1:10,000 (ov, 
4ºC) 
Calretinin (Sigma)  Calcium binding protein/ interneuronal marker H-3300, 1:3000 (ov, 
4ºC) 
Parvalbumin (Swant) Calcium binding protein/ interneuronal marker H-3300, 1:5000 (ov, 
4ºC) 
Neuropeptide Y 
(Sigma) 
Neuropeptide / GABAergic neurones H-3300, 1:4000 (ov, 
4ºC) 
KCC2 (Autogen 
Bioclear) 
K+/Cl- Cotransporter/GABAergic neurones 1:600 (ov, 4ºC) 
KCC1 (Gift) (NKCC1) Na+/K+/Cl- Cotransporter isoform/GABAergic neurones H-3301, 1:500 (60, RT) 
NEURO- 
DEGENERATI
VE* 
AT8 (Innogenetics) Phosphorylated microtubule associated tau protein ER1, 1:1200 (20, RT) 
APP (EMD) amyloid precursor protein ER1, 1:800 (20, RT) 
p62  (BD)  Sequestosome-1/ targets specific cargoes for autophagy ER2, 1:100 (20, RT) 
Mitochondria 
(Abcam) 
Anti-mitochondrial antibody ER2, 1:200 (20, RT) 
MTOR 
PATHWAY 
pS6 Ser240/244 
(Cell Signaling Tech.) 
phosphorylated-S6 ribosomal protein at ser 240/244  H-3301, 1:1000 (ov, 
4ºC) 
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Table 1. List of immunohistochemical markers applied to the study of multinodular vacuolated neuronal 
tumour (MVNT). For markers in the groups of antibodies indicated with * between 4 to 8 cases with MVNT 
were studied with each marker due to limited availability of sections ; for remaining cases, all markers were 
examined in all cases.  ≠PDGFRbeta in this series was used to label pericytes as well as small multipolar NG2-like 
glial cells as previously reported (18, 55) ; reliable labelling of NG-2 cells with NG2 or PDGFRalpha was not 
achieved in these cases. Antigen retrieval buffers (buffers used in auto-immunostainer is in bold): ENZ1, Bond 
enzyme concentrate and diluent (Leica, Milton Keynes, UK); ER1, Bond citrate-based buffer (Leica, Milton 
Keynes, UK); ER2 Bond EDTA-based buffer (Leica, Milton Keynes, UK); H-3301 Vector’s Tris-based buffer pH9.0 
(Vector Lab, Peterborough, UK); H-3300 Vector’s citrate-based buffer pH6.0 (Vector Lab, Peterborough, UK);  
SC Sodium Citrate buffer pH6. RT room temperature; OV overnight).  Suppliers: EMD Millipore, Watford, UK; 
Sternberger, Maryland, US; DAKO, Cambridgeshire, UK; Sigma Aldrich, Dorset, UK; Abcam, Cambridge, UK; Santa Cruz Bio. 
Heidelberg, Germany; Cell Signaling Tech. Boston, US; Swant, Marly, Switzerland; Autogen Bioclear Ltd, Wiltshire, UK; BD 
Transduction Lab., Oxford, UK; Spring Bioscience, California,US; Dianova ,Hamburg, Germany. 
 
 
ACTIVATION pS6 Ser 235/236 
(Cell Signaling Tech.) 
phosphorylated-S6 ribosomal protein at serine 235/236  H-3301, 1:250 (ov, 
4ºC) 
CELL CYCLE 
AND 
TUMOUR 
MUTATION 
MARKERS 
MCM2 (BD) Mini chromosome maintenance protein / cells licensed for 
replication 
H-3301, 1:900 (ov, 
4ºC) 
Ki67  (DAKO) Nuclear protein/ proliferating cells ER2, 1:200 (20, RT) 
BRAF V600E (Spring 
Bioscience) 
V600E mutation to Serine/threonine-protein kinase B-raf/ 
Upregulated in benign and malignant human tumours 
ER2, 1:50 (20, RT) 
IDH1 (Dianova) Isocitrate Dehydrogenase 1/ low grade and secondary high 
grade gliomas 
ER2, 1:64 (20, RT) 
ATRX (Sigma) Alpha thalassemia/mental retardation syndrome x-linked 
(is SNF2 family of helicase and ATPases) / gliomas 
ER2, 1:500 (20, RT) 
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Cas
e 
Presenting 
symptoms 
Age 
onset 
of 
seizure
s 
(years) 
Age at 
surgery 
(PM) 
/Gender 
Type of 
seizures 
Localisation 
Structures involved 
Type of surgical 
resection 
Any other  
relevant 
neurology 
Outcome 
following surgery. 
Seizure 
control/tumour 
recurrence 
[Period of follow 
up] 
1 Seizures  39 59 / F PS, GS Left temporal lobe, 
parahippocampal gyrus, 
hippocampus and 
amygdala 
Left temporal lobectomy,  
hippocampectomy and 
resection of amygdala 
Declining verbal 
memory post 
operatively. 
Depression 
Continued seizures 
(1-3 nocturnal 
seizure per week)/ 
No recurrence of 
tumour 
[9 years] 
2 Seizures/tem
poral lobe 
epilepsy 
 
‘epilepsy 
many 
years’ 
32 / F PS Right temporal lobe, 
parahippocampal gyrus, 
hippocampus and 
amygdala 
Right temporal lobectomy,  
hippocampectomy and 
resection of amygdala 
Impaired non-
verbal learning. 
Migraine. 
Seizure-free / no 
recurrence  
[6 years] 
3 Seizures 10 27 / F PS, GS Left amygdala and 
hippocampus 
Left temporal lobectomy,  
hippocampectomy and 
resection of amygdala 
Psychosis 
following 
temporal 
lobectomy. 
Seizure-free / No 
recurrence on MRI 
[14 years] 
4 Breathing 
difficulties 
NA 62 / M No 
history of 
epilepsy 
Right occipital lobe Post mortem : whole brain  Braak stage V AD 
diagnosed at PM 
Cause of death 
mesothelioma. 
NA 
5  Visual 
symptoms/ 
seizures 
65 67 /F PS Right posterior parietal - 
temporal lobe lesion 
Lesionectomy None No neurological 
deficit and 
seizure free /lesion 
stable  
[2 years] 
6 Seizures/ 
Speech arrest 
47 48/F PS, GS Left middle temporal 
gyrus 
Lesionectomy / awake 
craniotomy 
None Seizure-free 
/Residual tumour 
but no progression 
on MRI 
 [2 years] 
7  Seizures  6/M  Left temporal Left temporal neocortex, 
hippocampectomy 
 Seizure-free/ 
residual tumour on 
MRI but no 
progression 
[17 months] 
8 Seizures 21 54/M PS,GS Right temporal lobe, 
parahippocampal gyrus, 
fusiform gyrus and 
hippocampus 
Temporal lobe, 
hippocampectomy 
Post-ictal 
psychosis/post 
operative facial 
weakness 
Seizure-free/No 
progression 
[10 months] 
9 Epilepsy  41/F  Right mesial temporal 
lesion 
Temporal lobe resection  Partial resection but 
no progression on 
MRI 
 
10 
 
Epilepsy  55/M CPS Temporal lobe and 
temporal pole 
Temporal lobe resection  Recent surgery , 
Limited follow up 
data 
 
Table 2: Clinical details of cases in current series, location, salient MRI features and outcome 
following surgery. Case 1 was previously reported (Ratilal et al., 2007). PM = post mortem, AD = 
Alzheimer’s’ disease, AED= anti-epileptic drugs, NA=not applicable, RTA = road traffic accident, PS = 
partial seizures, GS=generalised seizures 
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SUFU 8 
108 (1018) 
[chr10: 104359297] 
[chr10: 102599540] 
GT AS (340) c.1018G>T 
rs34135
067 
Missense 
mutation of 
unknown 
significance 
1 
[2] 
1/22 0/8 
EZH2 6 
69 (553) 
[chr7:g.148525904 
(hg19)] 
G -> C 
D -> H 
(185) 
c.553G>C 
rs23024
27 
COSM3
762469 
COSM3
762470 
Missense 
mutation of 
unknown 
significance 
1 
[8] 
0/22 0/8 
DEPD
C5 
9 
-43 
[chr22:32179850] 
[chr22: 31783864] 
GC Intron 
c.484-
43G>C 
rs13828
6 
Intron 
8 
[all cases 
tested ; 
1,2,3,5,6,8,9
,10] 
 
22/22 6/8 
NPRL3 11 
-102 
[chr16:142825] 
[chr16:92827] 
AG Intron 
c.1032-
102A>G 
rs25416
18 
Intron 
5 
[2,3,5,6,9] 
20/22 0/8 
CIC 20 
74 (4533) 
[chr19: 42799049] 
[chr19: 42294897] 
CT II (1511) c.4533C>T 
rs10520
23 
COSM3
756833 
Silent 
6 
[1,3,,6,8,9,1
0] 
14/22 4/8 
PIK3C
A 
6 
-17 
[chr3:178922274] 
[chr3: 179204486] 
CA Intron 
c.1060-
17C>A 
rs26998
96 
Intron 
7 
[2,3,5,6,8,9,
10] 
19/22 6/8 
SMO 
3 
-26 
[chr7:128845018] 
[chr7:129205177] 
CT Intron c.538-26C>T 
rs27030
91 
Intron 
8 
[all cases 
tested ; 
1,2,3,5,6,8,9
,10] 
22/22 8/8 
6 
24 (1164) 
[chr7:128846328] 
[chr7:129206487] 
GC 
G -> G 
(388) 
c.1164G>C 
rs22286
17 
COSM4
004294 
Silent 
8 
[all cases 
tested ; 
1,2,3,5,6,8,9
,10] 
 
21/22 7/8 
TP53 4 
119 (215) 
[chr17:7579472] 
CG PR (72) c.215C>G 
rs10425
22 
COSM3
766190
Polymor-
phism 
8 
[all cases 
tested ; 
20/22 
 
7/8 
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Table 3.  Mutations and recurring, common single nucleotide polymorphisms identified by next 
generation sequencing in a study of nine multinodular vacuolating neuronal tumours.  
[chr17:7676154] -93 
COSM2
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1,2,3,5,6,8,9
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